This post is sponsored by the Ohio Venture Association.
The Ohio Venture Association will focus on the world of biomedical technology when Frank Douglas, President and CEO of the Akron BioInnovation Institute, speaks at its upcoming lunch meeting.
“The BioInnovation Institute in Akron represents a best-in-class model for the future of healthcare delivery and innovation,” said Douglas. “The history of the city of Akron, combined with outstanding contributions from each of the founding partners, has created a bedrock for excellence in the field of bioinnovation.”
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The Ohio Venture Association lunch will be held on Friday, Dec. 10, at The Union Club, 1211 Euclid Avenue. Parking can be accessed from East 12th Street. Networking starts at 11:30, followed by lunch and the presentation at noon.
Former founder and executive director of Massachusetts Institute of Technology’s (MIT) Center of Biomedical Innovation, Douglas is an award-winning industry veteran with more than 24 years of experience in healthcare, pharmaceutical research, and biotechnology.
Douglas joined the BioInnovation Institute in Akron after serving as senior fellow, Ewing M. Kauffman Foundation; senior partner, Puretech Ventures; and chief scientific advisor, Bayer Healthcare, AG. Prior to that, he served as professor of the Practice at MIT Schools of Management, Engineering, and Science and the Harvard-MIT Division of Health Sciences and Technology, an interdisciplinary educational and research program.
The BioInnovation Institute in Akron is transforming Akron into a model for biomedical discovery and enterprise. Together, the five operating founders of the Institute — Akron Children’s Hospital, Akron General Health System, Northeastern Ohio Universities Colleges of Medicine and Pharmacy (NEOUCOM), Summa Health System and The University of Akron — have a world-class reputation in research, education and health.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Funding to create the BioInnovation Institute in Akron began with a grant from the John S. and James L. Knight Foundation, lead funder and founding partner of the Institute. The State of Ohio joined the founding members as a key partner in the development of the Institute from concept to reality. Through the collaboration of these complementary institutions, the goal of this initiative is to expand Akron’s rich legacy in materials science to pioneer the next generation of life-enhancing and life-saving bioinnovations for the 21st century.
The cost of the lunch is $25 for members with a reservation or $35 without a reservation. Non-members pay $45 with a reservation or $55 without a reservation. To register, visit the Ohio Venture Association’s website: www.ohioventure.org.
